Crosspoint Capital Strategies’s Eli Lilly LLY Stock Holding History

Crosspoint Capital Strategies’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-248	Closed	-$17K	–	512
2015 Q4	$17K	Buy	+248	New	+$20.6K	﹤0.01%	620
2015 Q3	–	Sell	-170	Closed	-$14K	–	843
2015 Q2	$14K	Hold	170	–	–	﹤0.01%	459
2015 Q1	$12K	Buy	170 +139	+448%	+$9.9K	0.01%	380
2014 Q4	$2K	Hold	31	–	–	﹤0.01%	676
2014 Q3	$2K	Sell	31 -45	-59%	-$2.85K	﹤0.01%	459
2014 Q2	$5K	Sell	76 -1,500	-95%	-$89.5K	﹤0.01%	444
2014 Q1	$93K	Hold	1,576	–	–	0.04%	198
2013 Q4	$94K	Buy	+1,576	New	+$78.9K	0.03%	202

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Crosspoint Capital Strategies's LLY Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Eli Lilly (LLY) in Q1 2016, closing a stake of 248 shares — an estimated $17K sold.

Crosspoint Capital Strategies first reported a position in LLY in Q4 2013 and held it in 8 quarters. The position peaked at $94K in Q4 2013. 1,151 funds tracked by Wall St. Rank hold LLY as of Q1 2016.

Crosspoint Capital Strategies reported no remaining Eli Lilly position as of Q1 2016 after selling out during the quarter.
Crosspoint Capital Strategies sold 248 Eli Lilly shares in Q1 2016, an estimated $17K.
Crosspoint Capital Strategies first reported a position in Eli Lilly in Q4 2013 and held it in 8 quarters.
Crosspoint Capital Strategies's Eli Lilly position peaked at $94K in Q4 2013.
1,151 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.